Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
Ibuprofen vs ARALEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Non-selective inhibition of cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, leading to anti-inflammatory, analgesic, and antipyretic effects.
Chloroquine, a 4-aminoquinoline, accumulates in acidic organelles such as food vacuoles of malaria parasites, inhibiting heme polymerase and preventing the conversion of toxic heme to hemozoin. It also interferes with DNA synthesis and repair by intercalating into DNA. Additionally, it has immunomodulatory effects via inhibition of Toll-like receptors and cytokine production.
Rheumatoid arthritis,Osteoarthritis,Mild to moderate pain,Dysmenorrhea,Fever reduction,Juvenile idiopathic arthritis,Patent ductus arteriosus closure (off-label),Pericarditis (off-label),Gout (off-label)
Treatment of uncomplicated malaria caused by susceptible strains of Plasmodium vivax, P. malariae, P. ovale, and P. falciparum,Prophylaxis of malaria in areas with chloroquine-sensitive P. falciparum,Treatment of extraintestinal amebiasis (as amebicide) and giardiasis (off-label),Disease-modifying antirheumatic drug (DMARD) for rheumatoid arthritis and lupus erythematosus (off-label)
200-800 mg orally every 6-8 hours; maximum 3200 mg/day.
Adults: 500 mg (300 mg base) orally once weekly on the same day each week for prophylaxis of malaria; 1 g (600 mg base) orally initially, followed by 500 mg (300 mg base) at 6, 24, and 48 hours for treatment of acute malaria.
Terminal elimination half-life is 2-4 hours; no accumulation with repeated dosing in normal renal function.
Terminal elimination half-life ranges from 30 to 60 days (mean ~45 days) due to extensive tissue binding; clinical context: prolonged half-life allows weekly dosing for malaria prophylaxis.
Primarily hepatic via CYP2C9 (major) and CYP2C8 (minor); also undergoes glucuronidation. Metabolites are inactive.
Chloroquine is extensively metabolized in the liver via cytochrome P450 enzymes, primarily CYP2C8 and CYP3A4, to active metabolites such as desethylchloroquine. It has a long elimination half-life of approximately 1-2 months.
Renal excretion of conjugated metabolites (about 90% as glucuronide and sulfate conjugates, <10% as unchanged drug); minor biliary/fecal elimination (<5%).
Primarily renal (approximately 70% as unchanged drug); minor biliary/fecal (about 10-20%).
99% bound primarily to albumin.
Approximately 50-60% bound; primarily to albumin and alpha-1-acid glycoprotein.
0.1-0.2 L/kg; low Vd consistent with high protein binding and limited tissue distribution.
Very large, 100-200 L/kg; extensive tissue distribution (liver, spleen, kidney, lungs, melanin-containing tissues).
Oral: 80-100% (rapidly and completely absorbed).
Oral: 80-90%.
GFR 30-60 m L/min: no adjustment needed; GFR 15-29 m L/min: 200 mg every 12 hours; GFR <15 m L/min: avoid use.
For malaria prophylaxis: No adjustment necessary. For treatment: If Cr Cl < 10 m L/min, reduce dose by 50%.
Child-Pugh A: no adjustment; Child-Pugh B: use with caution, reduce dose by 50%; Child-Pugh C: avoid use.
No formal guidelines; use caution in severe hepatic impairment due to potential accumulation. Consider dose reduction in Child-Pugh class C.
5-10 mg/kg/dose orally every 6-8 hours; maximum 40 mg/kg/day.
Prophylaxis: 5 mg/kg base (8.3 mg/kg salt) orally once weekly, max 300 mg base. Treatment: 10 mg/kg base (16.7 mg/kg salt) orally initially, followed by 5 mg/kg base at 6, 24, and 48 hours, max 600 mg base on day 1.
Start at lowest effective dose (200 mg every 8-12 hours); maximum 400 mg/day due to increased risk of GI bleeding and renal impairment.
No specific adjustments; consider age-related renal impairment and potential increased risk of QT prolongation. Monitor for cardiac effects.
NSAIDs cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. Risk may increase with duration of use. Contraindicated for treatment of perioperative pain in coronary artery bypass graft surgery.
Retinopathy: Irreversible retinal damage including retinopathy and visual disturbances; risk increases with cumulative dose and duration of use; contraindicated in patients with pre-existing retinopathy; baseline and periodic ophthalmologic exams required.
Cardiovascular thrombotic events,Gastrointestinal ulceration, bleeding, perforation,Hypertension,Heart failure exacerbation,Renal toxicity (including acute renal failure, interstitial nephritis),Anaphylactoid reactions,Serious skin reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis),Hematologic effects (e.g., anemia, prolonged bleeding time),Hepatic impairment,Asthmatic reactions in aspirin-sensitive patients
Retinopathy risk with prolonged use; cardiac effects including conduction disorders (e.g., QT prolongation) and cardiomyopathy; exacerbation of psoriasis and porphyria; neuropsychiatric effects (e.g., psychosis, seizures); hematologic toxicity (eg, agranulocytosis, aplastic anemia); hypoglycemia; myopathy; ototoxicity. Use with caution in hepatic or renal impairment, G6PD deficiency, and pregnancy (benefit vs risk).
Hypersensitivity to ibuprofen or any NSAID,History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs,Perioperative pain in coronary artery bypass graft surgery,Active gastrointestinal bleeding, ulceration, or perforation,Advanced renal disease,Pregnancy (third trimester),Severe heart failure (NYHA class IV),Cerebrovascular bleeding
Hypersensitivity to chloroquine or 4-aminoquinolines; pre-existing retinopathy of any etiology; concurrent use with other agents causing retinal toxicity (e.g., hydroxychloroquine, tamoxifen); porphyria; psoriasis (relative, may exacerbate); neuromyopathy (relative); severe hepatic or renal impairment (relative).
Alcohol: increases GI irritation and bleeding risk. Grapefruit juice: no significant interaction. High-fat meals may delay absorption but do not reduce overall bioavailability.
Avoid grapefruit juice as it may increase chloroquine levels. No other significant food interactions.
First trimester: NSAID use associated with increased risk of miscarriage and congenital anomalies (e.g., cardiac defects, gastroschisis). Second trimester: Avoid due to potential oligohydramnios and fetal renal impairment. Third trimester: Contraindicated; risk of premature ductus arteriosus closure, persistent pulmonary hypertension, oligohydramnios, and fetal nephrotoxicity.
Pregnancy category C. First trimester: No conclusive evidence of major malformations in human studies, but animal studies show embryotoxicity and fetotoxicity. Second and third trimesters: Risk of sensorineural hearing loss, vestibular damage, and retinal toxicity in the fetus if used for prolonged periods or at high doses; accumulation in fetal ocular tissues reported.
Ibuprofen is compatible with breastfeeding. M/P ratio approximately 0.6–1.1. Transfer into breast milk is low; relative infant dose <1% maternal weight-adjusted dose. Preferred NSAID during lactation due to short half-life and low infant exposure.
Excreted in breast milk in small amounts (M/P ratio approximately 0.44). American Academy of Pediatrics considers compatible with breastfeeding, but caution is advised in infants with glucose-6-phosphate dehydrogenase deficiency or hemolytic disease. Monitor infant for rash, retinal changes, and hemolysis.
Physiological changes in pregnancy (increased volume of distribution, renal clearance) may reduce serum concentrations. However, no specific dose adjustment is routinely recommended. Use lowest effective dose for shortest duration. Avoid in third trimester.
No specific dose adjustment recommended for pregnancy; pharmacokinetic changes (increased volume of distribution, decreased plasma concentrations) may require therapeutic drug monitoring, but empirical dose adjustments are not established. Use lowest effective dose and shortest duration.
Ibuprofen has a ceiling effect for analgesia; exceeding 400 mg per dose provides minimal additional pain relief but increases GI and cardiovascular risks. Avoid use in patients with severe renal impairment (Cr Cl <30 m L/min) or active peptic ulcer disease. In asthma patients, note that NSAIDs can trigger bronchospasm in approximately 10% of aspirin-sensitive individuals. For acute pain, a single dose of 400-800 mg is effective; for chronic use, use the lowest effective dose for the shortest duration. Ibuprofen is highly protein-bound and may displace warfarin, increasing INR; monitor closely.
Chloroquine (Aralen) can cause retinal toxicity; cumulative dose should not exceed 200g. Use with caution in G6PD deficiency. Can prolong QTc interval; avoid with other QTc-prolonging drugs.
Take with food or milk to reduce stomach upset.,Do not exceed 1200 mg per day without a doctor's approval; maximum OTC dose is 400 mg every 4-6 hours.,Avoid alcohol while taking ibuprofen to reduce the risk of stomach bleeding.,Stop taking and contact your doctor if you experience signs of stomach bleeding: black or bloody stools, vomiting blood, or severe abdominal pain.,Ibuprofen can increase risk of heart attack or stroke, especially with long-term use or high doses; discuss your cardiovascular risk with your doctor.,Do not take ibuprofen if you are pregnant (especially in the third trimester) unless directed by your doctor, as it can harm the unborn baby.
Take with food to reduce gastrointestinal upset.,Do not exceed prescribed dose; overdose can be fatal.,Report any vision changes immediately; regular eye exams are required.,Avoid alcohol as it may increase risk of liver toxicity.,Inform your doctor if you have a history of heart rhythm problems.
"Concomitant use of Ibuprofen (a nonsteroidal anti-inflammatory drug, NSAID) and Methylprednisolone (a systemic corticosteroid) synergistically increases the risk of gastrointestinal (GI) ulceration, bleeding, and perforation due to additive inhibition of prostaglandin synthesis and mucosal protection. Additionally, Ibuprofen may potentiate the immunosuppressive effects of Methylprednisolone, elevating infection risk. This interaction can lead to serious clinical outcomes, including acute GI hemorrhage, perforation, and impaired wound healing."
"The combination of olopatadine, an antihistamine with sedative properties, and ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), may result in additive central nervous system (CNS) depression, leading to increased sedation, dizziness, and impaired psychomotor function. Ibuprofen can inhibit the metabolism of olopatadine via competition for hepatic CYP450 enzymes, potentially elevating olopatadine plasma concentrations and prolonging its systemic effects. Clinically, patients may experience exacerbated drowsiness, reduced alertness, and increased risk of falls or accidents, especially in the elderly or those with compromised hepatic function."
"Ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), can decrease the metabolism of pioglitazone, a thiazolidinedione antidiabetic agent, by inhibiting cytochrome P450 2C8 (CYP2C8) enzyme activity. This inhibition elevates plasma concentrations of pioglitazone, potentially enhancing its hypoglycemic effects and increasing the risk of adverse reactions such as edema, weight gain, and heart failure exacerbation. Clinically, concomitant use may lead to improved glycemic control but also raises concerns for dose-dependent toxicities, necessitating careful monitoring and possible dose adjustment of pioglitazone."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about Ibuprofen vs ARALEN, answered by our medical review team.
Ibuprofen is a NSAID that works by Non-selective inhibition of cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, leading to anti-inflammatory, analgesic, and antipyretic effects.. ARALEN is a Antimalarial that works by Chloroquine, a 4-aminoquinoline, accumulates in acidic organelles such as food vacuoles of malaria parasites, inhibiting heme polymerase and preventing the conversion of toxic heme to hemozoin. It also interferes with DNA synthesis and repair by intercalating into DNA. Additionally, it has immunomodulatory effects via inhibition of Toll-like receptors and cytokine production.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between Ibuprofen and ARALEN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of Ibuprofen is: 200-800 mg orally every 6-8 hours; maximum 3200 mg/day.. The standard adult dose of ARALEN is: Adults: 500 mg (300 mg base) orally once weekly on the same day each week for prophylaxis of malaria; 1 g (600 mg base) orally initially, followed by 500 mg (300 mg base) at 6, 24, and 48 hours for treatment of acute malaria.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between Ibuprofen and ARALEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. Ibuprofen is classified as Category D/X. First trimester: NSAID use associated with increased risk of miscarriage and congenital anomalies (e.g., cardiac defects, gastroschisis). Second trimester: Avoid due to potential o. ARALEN is classified as Category C. Pregnancy category C. First trimester: No conclusive evidence of major malformations in human studies, but animal studies show embryotoxicity and fetotoxicity. Second and third tri. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.